Antoine Gavoille

Antoine Gavoille

Auto-generated profile, based on publicly available information

Antoine Gavoille

Service de Neurologie, Sclérose en plaques, Pathologies de la myéline et neuro-inflammation, Hospices Civils de Lyon, Bron, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
AGAntoine Gavoille
Antoine Gavoille
FRFabien Rollot
Fabien Rollot
RCRomain Casey
Romain Casey
MDMarc Debouverie
Marc Debouverie
EPEmmanuelle Le Page
Emmanuelle Le Page
OIon behalf of Observatoire Français de la Sclérose en Plaques (OFSEP) Investigators
on behalf of Observatoire Français de la Sclérose en Plaques (OFSEP) Investigators
Background and Objectives The question of the long-term safety of pregnancy is a major concern in patients with multiple sclerosis (MS), but its study is biased by reverse causation (women with higher disability are less likely to experience pregnancy). Using a causal inference approach, we aimed to estimate the unbiased long-term effects of pregnancy on disability and relapse risk in patients with MS and secondarily the short-term effects (during the perpartum and postpartum years) and delayed effects (occurring beyond 1 year after delivery). Methods We conducted an observational cohort study with data from patients with MS followed in the Observatoire Français de la Sclérose en Plaques registry between 1990 and 2020. We included female patients with MS aged 18–45 years at MS onset, clinically followed up for more than 2 years, and with ≥3 Expanded Disease Status Scale (EDSS) measurements. Outcomes were the mean EDSS score at the end of follow-up and the annual probability of relapse during follow-up. Counterfactual outcomes were predicted using the longitudinal targeted maximum likelihood estimator in the entire study population. The patients exposed to at least 1 pregnancy during their follow-up were compared with the counterfactual situation in which, contrary to what was observed, they would not have been exposed to any pregnancy. Short-term and delayed effects were analyzed from the first pregnancy of early-exposed patients (who experienced it during their first 3 years of follow-up). Results We included 9,100 patients, with a median follow-up duration of 7.8 years, of whom 2,125 (23.4%) patients were exposed to at least 1 pregnancy. Pregnancy had no significant long-term causal effect on the mean EDSS score at 9 years (causal mean difference [95% CI] = 0.00 [−0.16 to 0.15]) or on the annual probability of relapse (causal risk ratio [95% CI] = 0.95 [0.93–1.38]). For the 1,253 early-exposed patients, pregnancy significantly decreased the probability of relapse during the perpartum year and significantly increased it during the postpartum year, but no significant delayed effect was found on the EDSS and relapse rate. Discussion Using a causal inference approach, we found no evidence of significantly deleterious or beneficial long-term effects of pregnancy on disability. The beneficial effects found in other studies were probably related to a reverse causation bias.

5 April 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
AGAntoine Gavoille
Antoine Gavoille
ADAnne-Claire Desbois
Anne-Claire Desbois
BJBastien Joubert
Bastien Joubert
CDCécile-Audrey Durel
Cécile-Audrey Durel
CAClément Auvens
Clément Auvens
PSPascal Sève
Pascal Sève
Background and objectives: Spinal cord sarcoidosis is a rare manifestation of sarcoidosis with a consequent risk of neurological sequelae for the patient. We investigated prognostic factors and efficacy of immunosuppressive treatments in a longitudinal cohort. Methods: We retrospectively studied patients with spinal cord sarcoidosis followed between 1995 and 2021 in seven centers in France. Patients with a definite, probable or possible spinal cord sarcoidosis according to the Neurosarcoidosis Consortium Consensus Group criteria and with a spinal cord involvement confirmed by MRI were included. We analyzed relapse or progression rate with a Poisson model, initial Rankin score with a linear model and change in the Rankin score during follow-up with a logistic model. Results: A total of 97 patients were followed for a median of 7.8 years. Overall mean relapse or progression rate was 0.17 per person-year and decreased over time. At last visit, 46 (47.4%) patients had a loss of autonomy (Rankin score ≥ 2). The main prognostic factors significantly associated with relapse or progression rate were gadolinium enhancement (relative rate [95% CI]: 0.61 [0.4, 0.95]) or meningeal involvement (relative rate [95% CI]: 2.05 [1.31, 3.19]) on spinal cord MRI, and cell count (relative rate [95% CI] per 1 log increase: 1.16 [1.01, 1.33]) on CSF analysis. Relapse or progression rate was not significantly associated with initial Rankin score or EDSS. TNF α antagonists significantly decreased relapse or progression rate compared with corticosteroids alone (relative rate [95% CI]: 0.33 [0.11, 0.98]). Azathioprine was significantly less effective than methotrexate on relapse or progression rate (relative rate [95% CI]: 2.83 [1.04, 7.75]) and change in Rankin score (mean difference [95% CI]: 0.65 [0.23, 1.08]). Discussion: Regarding the relapse or progression rate, meningeal localization of sarcoidosis was associated with a worse prognosis; TNF α antagonists resulted in a significant decrease compared to corticosteroids alone; and methotrexate was more effective than azathioprine. Classification of Evidence: This study provides Class IV evidence that in individuals with spinal cord neurosarcoidosis, TNF α antagonists were associated with decreased relapse or progression rate compared to corticosteroids alone, but other therapies showed no significant benefit.

26 August 2025 in Neurology
Verified
Journal Article
Closed access
AGAntoine Gavoille
Antoine Gavoille
ELEmmanuelle Leray
Emmanuelle Leray
RMRomain Marignier
Romain Marignier
FRFabien Rollot
Fabien Rollot
RCRomain Casey
Romain Casey
JGJérôme Grimaud
Jérôme Grimaud
In women with multiple sclerosis (MS), the therapeutic strategy may be influenced by the anticipation of future pregnancies, leading to underexposure to disease-modifying therapies (DMTs) and highly effective DMTs (HEDMTs) compared with men. We aimed to evaluate potential therapeutic inertia in women with MS and explore its causes. We performed a retrospective cohort study based on data extracted on June 2023 from the Observatoire Français de la Sclérose en Plaques for all patients with a relapsing-remitting MS onset between 18 and 40 years. The primary outcome was the annual probability of receiving a DMT, accounting for sex, disease severity, and pregnancy/postpartum periods. Secondary outcomes were the annual probability of receiving a HEDMT, each DMT separately, and interaction of the effect of sex with calendar year, patient age, and disease duration. We used a longitudinal logistic model with generalized estimating equations and an inverse-probability-of-censoring weighting. We included 22,657 patients with MS; 16,857 (74.4%) were female, mean (SD) age at onset was 29.0 (6.0) years, and median (interquartile range) follow-up duration was 11.6 (6.6-17.3) years. Women were significantly less likely to receive a DMT (odds ratio [OR] 0.92, 95% CI 0.87-0.97) or a HEDMT (OR 0.80, 95% CI 0.74-0.86). This difference appeared 2 years after disease onset for DMTs and 1 year for HEDMTs, and did not differ significantly according to patient's age. Teriflunomide, sphingosine-1-phosphate receptor modulators, and anti-CD20s were significantly underused in women throughout their entire period of availability; interferons β (IFN-β) and natalizumab were initially less used and then equally after some time; glatiramer acetate and fumarates were first used equally, then more frequently in women. The proportion of treated women, analyzed from the first childbirth of 5,268 women, began to decline 18 months before childbirth, from 42.6% to 27.9% at the estimated time of conception. Women with MS were significantly less exposed to DMTs compared with men. Anticipation of pregnancy was probably an important factor underlying this difference, but also sex-specific therapeutic inertia. Neurologists and patients should be educated on the most recent recommendations on the use of DMTs in the context of pregnancy to avoid deleterious therapeutic inertia.

1 November 2020 in Autoimmunity Reviews
Verified
Journal Article
Closed access
AGAntoine Gavoille
Antoine Gavoille
MVMichel Vincent
Michel Vincent
LKLize Kiakouama
Lize Kiakouama
MCMikael Catinon
Mikael Catinon
MLMedhi Lamkhioued
Medhi Lamkhioued
Pascal SèvePascal Sève
Pascal Sève

14 June 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
SVSandra Vukusic
Sandra Vukusic
FHFlorian Hubben
Florian Hubben
AGAntoine Gavoille
Antoine Gavoille
YMYannis Malek
Yannis Malek
OCOlivier Casez
Olivier Casez
JSJérôme de Seze
Jérôme de Seze
Background: The biosimilar drug of natalizumab was marketed with a new anti-John Cunningham virus (JCV) assay (Immunowell TM ). Objectives: To compare the performance of the Immunowell TM JCV assay to Stratify TM , the reference one. Methods: We analyzed retrospectively serological results from patients with multiple sclerosis (MS) followed in four French MS centers and tested simultaneously in routine with both tests. Results: Two hundred and fifty-nine patients were included. Results were positive in 23.6% with Stratify TM and 61.4% with Immunowell TM . A binary discordance was found in 37.8%. Sensitivity and negative predictive value were 100%, with lower specificity (50.5%) and positive predictive value (38.4%) for Immunowell TM . According to index value cutoffs, 42.9% of the results showed discordances, with a systematic higher risk estimate for Immunowell TM . Most of them (83/111) were negative with Stratify TM and at low risk of progressive multifocal leukoencephalopathy (PML) (<0.8) with Immunowell TM . Eighteen were upgraded to intermediate risk (0.8–1.4) and 10 to high risk (⩾1.4). Conclusions: The Immunowell TM JCV IgG assay is reliable to detect patients at risk of progressive multifocal leukoencephalopathy, but the high rate of discrepancy is challenging in deciding to continue on natalizumab or not.

18 May 2021 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
MFMaxime Fieux
Maxime Fieux
AGAntoine Gavoille
Antoine Gavoille
FSFabien Subtil
Fabien Subtil
SBSophie Bartier
Sophie Bartier
STStephane Tringali
Stephane Tringali
The ongoing COVID-19 pandemic has disrupted the surgical training of residents. There is a real concern that trainees will not be able to meet their training requirements. Low-fidelity surgical simulation appears to be an alternative for surgical training. The educational benefits of repeating ossiculoplasty simulations under a microscope have never been evaluated. With this study we aimed to evaluate the differences in performance scores and on a global rating scale before and after training on an ossiculoplasty simulator. In this quasi-experimental, prospective, single-centre, before-after study with blinded rater evaluation, residents performed five microscopic ossiculoplasty tasks with a difficulty gradient (sliding beads onto rods, the insertion of a partial prosthesis, the insertion of a total prosthesis, and the insertion of a stapedotomy piston under microscopic or endoscopic surgery) before and after training on the same simulator. Performance scores were defined for each task, and total performance scores (score/min) were calculated. All data were collected prospectively. Six out of seven intermediate residents and 8/9 novices strongly agreed that the simulator was an effective training device and should be included in the ENT residency program. The mean effect of training was a significant increase in the total performance score (+ 0.52 points/min, [95 % CI, 0.40–0.64], p < 0.001), without a significant difference between novice and intermediate residents. This preliminary study shows that techniques for middle-ear surgery can be acquired using a simulator, avoiding any risk for patients, even under lockdown measures.